Beijing Friendship Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1952-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- https://www.bfh.com.cn
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Phase 2
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: PD-1/PD-L1 inhibitor ,chemotherapy/targeting
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 172
- Registration Number
- NCT05809336
- Locations
- 🇨🇳
Qin li, Beijing, Beijing, China
Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis
Recruiting
- Conditions
- Chronic Hepatitis bNon-Alcoholic Fatty Liver Disease
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT05786963
- Locations
- 🇨🇳
Yameng Sun, Beijing, Select A State Or Province, China
Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy
Not Applicable
Recruiting
- Conditions
- Idiopathic Membranous Nephropathy
- Interventions
- Drug: Modified Ponticelli regimen
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT05782933
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
Phase 1
Recruiting
- Conditions
- Esophageal CarcinomaNeoadjuvant Immunotherapy
- Interventions
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 89
- Registration Number
- NCT05777707
- Locations
- 🇨🇳
Qin li, Beijing, Beijing, China
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Phase 3
Not yet recruiting
- Conditions
- PD-1 AntibodyHemophagocytic LymphohistiocytosisLymphomaEpstein-Barr Virus
- Interventions
- Drug: L-DEP and PD-1 antibody
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT05775705
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
PCI in Beijing Friendship Hospital
Recruiting
- Conditions
- Cardiovascular DiseasesPercutaneous Coronary Intervention
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 10000
- Registration Number
- NCT05728580
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
Not Applicable
Not yet recruiting
- Conditions
- IgG4 Related Disease
- Interventions
- Biological: CM310
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05728684
A New Risk Score for Predicting 1-year Mortality in Older r Maintenance Hemodialysis Patients.
Completed
- Conditions
- Older PatientMaintenance Hemodialysis
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 1500
- Registration Number
- NCT05699447
COVID-19 Infection and Idiopathic Membranous Nephropathy
Recruiting
- Conditions
- Idiopathic Membranous Nephropathy
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT05691179
- Locations
- 🇨🇳
Beijing Pinggu Hospital, Beijing, Beijing, China
🇨🇳Beijing Friedship Hospital, Beijing, Beijing, China
🇨🇳Beijing Liangxiang Hospital, Beijing, Beijing, China
Response Prediction in EBV-HLH Using Metabonomics Analysis
Not yet recruiting
- Conditions
- Hemophagocytic LymphohistiocytosesEBVMetabonomics
- Interventions
- Other: observational
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05677178
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath